Market Overview
Revelation Biosciences Inc. (NASDAQ: REVB) opened the trading session on Wednesday, 21 October 2026, at a price of USD 3.75—down 3.18 % from the previous close. The stock’s liquidity remained modest, with a volume of approximately USD 142.9 k and a market capitalization of USD 1.9 million. Over the last 24 hours, the company’s shares were exchanged on major markets at an average price of USD 3.75, reflecting a modest decline from the USD 9.11 simple moving average over the past 200 days.
In the broader context, Revelation’s performance is consistent with a broader downturn in the sector. Since the close of last month, the share price has fallen 51.93 %, underscoring the volatility that often accompanies clinical‑stage biopharmaceuticals.
Recent 52‑Week Trading
Revelation’s most recent 52‑week high, USD 40.60, was recorded on 23 January 2026, while the low, USD 3.08, occurred on 19 October 2026—indicating a relatively narrow trading range in the current year. The current trading level, therefore, sits closer to the lower end of that spectrum, suggesting that investors are still grappling with the company’s recent clinical milestones and regulatory outlook.
Peer Comparison
The performance of nearby stocks provides additional context for the current market sentiment:
| Stock | Recent 24‑Hour Change | Current Price (USD) | Market Cap (USD) |
|---|---|---|---|
| Geovax Labs (GOVX) | –4.2 % | 0.23 | 2.2 million |
| Digital Brands (DBGI) | –9.89 % | 2.03 | 2.2 million |
| Direct Communication Solutio (DCSX) | 0 % | 0.91 | 2.3 million |
| Focus Universal (FCUV) | +0.28 % | 3.40 | 2.3 million |
| Adagio Medical (ADGM) | +21.21 % | 0.12 | 2.2 million |
While most peers are trading lower, Adagio Medical’s sharp increase highlights that the sector remains highly fragmented; a single catalyst can have a disproportionate effect on a small‑cap listing.
Company Profile
Revelation Biosciences Inc. is a clinical‑stage biopharmaceutical enterprise headquartered in San Diego, California. The firm focuses on the development of therapeutics and diagnostics that harness the innate immune system to combat viral infections. As a global entity, the company seeks to provide solutions that span multiple markets and regulatory jurisdictions.
For further information on Revelation’s product pipeline, clinical trial data, and strategic initiatives, interested parties may consult the company’s publicly available resources at www.revbiosciences.com , which is accessible through Nasdaq’s institutional data portal.
